ARTV - Public offerings

ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug discovery, announced several business updates. First, the company has raised the next round of financing to advance its pipeline and continue to expand the scope and capabilities of its discovery platform. The Boehringer Ingelheim Venture Fund led the financing, which also included existing investors Insight Partners, Innospark, and Nor'easter Ventures, and new investor AB Magnitude. "We are grateful for the ongoing support of our strong investor base and welcome our new investor, AB Magni

Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025 Strengthened key leadership with cell therapy and autoimmune expertise across organization Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cel

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases Initial data for AlloNK® in autoimmune indications expected H1 2025 Robust balance sheet with cash, cash equivalents and investments of $199.6 million as of September 30, 2024, is expected to fund operations at least through end of 2026 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial

Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indicationsTreated first patient in Artiva sponsored Phase 1/1b trial in patients with class III or IV lupus nephritis (LN) and expanded trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune d